TABLE 3.
Reference method and analysis group | Sited | Value (%) of Xpert MRSA kit
|
|||
---|---|---|---|---|---|
Sensitivity | Specificity | PPVe | NPVf | ||
Direct culture | All | 88 | 92 | 53 | 99 |
Enrichment culture | All | 79 | 94 | 71 | 96 |
Nose | 84 | 92 | 67 | 97 | |
Throat | 63 | 98 | 83 | 93 | |
Groin/perineum | 92 | 94 | 69 | 99 | |
Amended resultsa | |||||
All patients | All | 90 | 97 | 86 | 98 |
Nose | 95 | 98 | 90 | 99 | |
Throat | 75 | 98 | 88 | 96 | |
Groin/perineum | 97 | 96 | 80 | 99 | |
Previously positive patientsb | All | 87 | 100 | 100 | 87 |
Nose | 93 | 100 | 100 | 88 | |
Throat | 73 | 100 | 100 | 77 | |
Groin/perineum | 95 | 100 | 100 | 96 | |
Patients who were not previously positivec | All | 96 | 97 | 62 | 100 |
Nose | 100 | 97 | 67 | 100 | |
Throat | 83 | 98 | 63 | 99 | |
Groin/perineum | 100 | 95 | 59 | 100 |
For further explanation of amended results, see Table 2, footnote c.
Analysis restricted to specimens from patients who were previously MRSA positive. With these specimens, kit-positive culture-negative specimens were also included as true positives because the patients were known to have been previously positive for MRSA.
Analysis restricted to specimens from patients with no record of being previously MRSA positive. With these specimens, kit-positive culture-negative specimens were also included as true positives if the patient was positive for MRSA at another site.
All, nose, throat, and groin/perineum.
PPV, positive predictive value.
NPV, negative predictive value.